Company Overview and News


Add NTLA
to your dashboard

Headline News

CRISPR Therapeutics Earnings Update: Maintains The Lead In Cas9 Clinical Trials

2017-11-10 seekingalpha
CRSP's update on their pipeline is encouraging - IND on track for 2017, first company in the CRISPR-Cas9 clinical space. (25-0)

NTLA / Intellia Therapeutics, Inc. - Stock Institutional Ownership and Shareholders - Fintel.io

2017-11-08 fintel.io
Intellia Therapeutics, Inc. (NASDAQ:NTLA) has 86 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 17,096,206 shares. Largest shareholders include Atlas Venture Associates IX, LLC, FMR LLC / Fidelity Management & Research, Orbimed Advisors Llc, BlackRock Inc., and Baker Brothers Advisors LP. (33-4)

Intellia Therapeutics Gears Up for Secondary Offering

2017-11-02 247wallst
Intellia Therapeutics Inc. (NASDAQ: NTLA) saw its shares take a dip on Thursday after the firm announced the pricing of its secondary offering. Looking at the chart, this seems to be the perfect time for an offering. The stock has run up about 94% in just 2017, excluding Thursday’s move, and now is a great time to capitalize on this. (1-0)

Calyxt Jumping Into A Crowded Space

2017-10-31 seekingalpha
Calyxt is using the excitement regarding cutting edge technologies in the genome editing space to support its product pipeline. (49-0)

Big Biotech In The CRISPR Game: Novartis And Vertex Lead The Pack

2017-10-23 seekingalpha
CRISPR Therapeutics and Intellia Therapeutics are partnered with the strongest large biotech plays in the space in Vertex and Novartis respectively. (310-1)

BRIEF-Intellia therapeutics demonstrates sustained and durable genome editing with CRISPR/Cas9

2017-09-26 reuters
* Intellia Therapeutics Inc - ‍investigational new drug-enabling activities on track for initiation in first half 2018​ (1-0)

Gene Editing Could Modify And Cure Disease: CRISPR Vs. TALENs

2017-09-21 seekingalpha
During the past decade, technology breakthroughs enabling the modification of complex genomes have changed the primary goal of research in biotechnology and synthetic biology: now research is focused not on “treatment” of diseases but on its modification and cure. The ability to directly edit living cells has brought gene therapy and precision medicine into a new era, one that will accelerate the pace of scientific research and increase the value of molecular diagnostic tests. (25-1)

CRISPR Field Patent Fight Extended: Focus On Science, Time Frames, Risks

2017-09-21 seekingalpha
CRISPR Therapeutics is currently under appreciated considering they are the closest company to beginning clinical trials. (101-2)

Is Regeneron Pharmaceuticals the Best Biotech Stock to Buy?

2017-08-18 fool
Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services.

3 Stocks That Could Make You Rich

2017-08-15 fool
Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services.

This Technology Could Make You Rich -- and Change the World As We Know It

2017-08-13 fool
Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. (0-3)

Behind The Hype, Crispr Is A Story Of Slow Progress And Acrimony

2017-08-03 seekingalpha
Some people reading this morning's mainstream press headlines about a Nature paper describing the correction of a germline mutation using Crispr (NASDAQ:CRSP) might be excused for thinking that we are entering a Gattaca-like world of designer babies.

CUSIP: 45826J105